However, the association between TP53 DNA alteration status and breast cancer neoadjuvant chemotherapy response has also been evaluated in in two large clinical trial cohorts: EORTC 10944/BIG 1-0030, a phase III trial comparing anthracycline versus anthracycline/taxane neoadjuvant therapy across breast cancer subtypes and the GeparSixto phase II trial31 evaluating anthracycline/taxane/platinum-based neoadjuvant therapy in triple-negative and HER2-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.